EUVIMEDEUVIMED entdecken
Fallbericht

Intrapleural Trastuzumab Therapy for Malignant Pleural Effusion from HER2 Overexpression in Metastatic Gastric Cancer

Elena Orlandi, Patrizia Mordenti, Adriano Zangrandi, Luigi Cavanna

Chemotherapy · 2014 · 60 (5-6) · 321-324

DOI: 10.1159/000437136 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Chemotherapy, online erschienen am 13.08.2015. Verfasst von Elena Orlandi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Hematology, Ospedale Guglielmo da Saliceto, Piacenza, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant pleural effusion (MPE) is an extremely common problem affecting cancer patients with advanced disease. The current therapy for MPE is local treatment, such as thoracentesis, chemical pleurodesis, intracavitary administration of anticancer drugs and systemic therapy. However, the management of MPE is still unsatisfactory. Case: We report a case of MPE secondary to human epidermal growth factor receptor 2 (HER2)-positive gastric cancer that was successfully treated with intrapleural trastuzumab. A 52-year-old male with metastatic HER2-positive gastric cancer received chemotherapy (FOLFOX4 regimen) plus trastuzumab; after 11 courses of chemotherapy, he developed right MPE refractory to systemic treatment and pleurodesis. A pleural biopsy performed during thoracoscopy showed pleural metastasis from HER2-positive gastric cancer. The patient received 2 courses of intrapleuric trastuzumab. After the second course, the MPE disappeared, and he continued systemic therapy with trastuzumab and docetaxel.

Conclusion

The safety was good, no local or systemic complications occurred, and the dyspnea secondary to MPE improved and subsequently disappeared. To our knowledge, this case is the first report on intrapleuric trastuzumab use to treat refractory MPE secondary to metastasis from HER2-positive gastric cancer. The treatment was well-tolerated and efficacious.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPleural CavityPleural Effusion, MalignantErb-b2 Receptor Tyrosine KinasesStomach NeoplasmsTrastuzumab

Substanzen

Antineoplastic AgentsErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology-Hematology, Ospedale Guglielmo da Saliceto, Piacenza, Italy.

Zitieren

APA

Orlandi, E., Mordenti, P., Zangrandi, A., & Cavanna, L. (2014). Intrapleural Trastuzumab Therapy for Malignant Pleural Effusion from HER2 Overexpression in Metastatic Gastric Cancer. Chemotherapy, 60(5-6), 321-324. https://doi.org/10.1159/000437136

Vancouver

Orlandi E, Mordenti P, Zangrandi A, Cavanna L. Intrapleural Trastuzumab Therapy for Malignant Pleural Effusion from HER2 Overexpression in Metastatic Gastric Cancer. Chemotherapy. 2014;60(5-6):321-324. doi:10.1159/000437136

BibTeX
@article{Orlandi2014,
  author = {Orlandi, Elena and Mordenti, Patrizia and Zangrandi, Adriano and Cavanna, Luigi},
  title = {Intrapleural Trastuzumab Therapy for Malignant Pleural Effusion from HER2 Overexpression in Metastatic Gastric Cancer},
  journal = {Chemotherapy},
  year = {2014},
  volume = {60},
  number = {5-6},
  pages = {321--324},
  doi = {10.1159/000437136}
}
Kostenlos starten →